Acute Cognition and Exercise

Obesity Clinical Trial

— ACE  

Official title:

Acute Exercise and Cognitive Function: Examining the Role of Weight Status and Exercise-Induced Myokines

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05078203
• Other study ID #: ACE
• Status: Completed
• Phase: N/A
• Start date: September 2, 2021
• Est. completion date: April 28, 2022

Study information

• Verified date: February 2024
• Source: University of Illinois at Urbana-Champaign
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The central hypothesis is that, while both groups will benefit from the exercise session, participants with obesity will exhibit greater gains in cognitive control, relative to healthy weight adults. Additionally, it is anticipated that the benefits of a single bout of exercise for cognitive control will be mediated by changes in exercise-induced myokines. These hypotheses will be tested by accomplishing three aims: Aim 1: Elucidate the changes in cognitive control following an acute bout of exercise, relative to a sedentary condition, in persons with and without obesity. Aim 2: To examine the effect of a single bout of exercise, relative to a sedentary condition, on myokines known to have neuroprotective effects i.e., BDNF and CTSB in both healthy weight and individuals with obesity. Aim 3: To link changes in exercise-induced myokines (i.e., BDNF and CTSB) to changes in cognitive function, following a single bout of exercise.

Description:

18 adults with healthy weight (BMI 18.5-25.0kg/m2) and 18 adults with obesity (BMI 30.0kg/m2) will be asked to complete a counter-balanced crossover trial. After initial baseline testing, participants will be asked to complete either an acute exercise bout or sedentary control session in a counter-balanced order. A cognitive testing battery accompanied by an electroencephalogram (EEG) will be administered following each session. Blood samples will be collected prior to, during, and following each throughout each testing condition.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 26
• Est. completion date: April 28, 2022
• Est. primary completion date: April 28, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Between ages 18 and 35
• No prior diagnosis of neurological disorders (e.g., autism spectrum disorder)
• No prior diagnosis of metabolic disease (e.g., diabetes, cardiovascular disease)
• No physical disability that would preclude the participant from completing a VO2max test
• Corrected vision (based on the minimal 20/20 standard needed to complete cognitive tasks)
• Not pregnant
• BMI between 18.5 and 25.0 kg/m2, or BMI greater than 30.0 kg/m2
• Readiness for exercise (determined through PAR-Q)

Exclusion Criteria:

• <18 years and >35 years
• Diagnosis of neurological disorders (e.g., autism spectrum disorder)
• Diagnosis of metabolic disease (e.g., diabetes, cardiovascular disease)
• Physical disability that would preclude the participant from completing a VO2max test
• Lack of corrected vision (based on the minimal 20/20 standard needed to complete cognitive tasks)
• Pregnancy
• BMI less than 18.5 kg/m2 or BMI greater than 25.0 but less than 30.0 kg/m2

Related Conditions & MeSH terms

• Obesity

Intervention

Behavioral:
• Exercise
36 minutes of Exercise

Locations

Country	Name	City	State
United States	University of Illinois at Urbana-Champaign	Urbana	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
University of Illinois at Urbana-Champaign

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Circulating Cathepsin B (CTSB) Myokine	Changes in peripheral myokine concentration	3 hours
Primary	Attentional Inhibition Accuracy	Behavioral performance measured as accuracy (%) during Flanker task	3 hours
Primary	Attentional Inhibition Reaction Time	Behavioral performance measured as response time (ms) during Flanker task	3 hours
Primary	Attentional Resource Allocation	Changes in P3 event related potential amplitude (microvolts) using a computerized flanker task	3 hours
Primary	Attentional Processing Speed	Changes in P3 event related potential latency (ms) using a computerized flanker task	3 hours
Primary	Relational Memory	Accuracy during a spatial reconstruction task	3 hours
Secondary	Brain derived neurotrophic factor (BDNF)	Changes in peripheral BDNF concentration	3 hours